The history of Endo can be traced back to 1920 to a
family-run pharmaceutical company originally called
Intravenous Products of America, Inc. In 1935 Intravenous
Products of America, Inc. changed its name to Endo Products.
In 1950, PERCODAN® was launched.
In 1970, E.I. du Pont de Nemours and Company (DuPont)
acquired Endo. In 1971, PERCOCET® was launched.
In 1994, DuPont Merck reestablished Endo as a separate
entity within the company. This entity was named Endo
Laboratories L.L.C. and served as DuPont Merck's generic
division.
Three executives of DuPont Merck acquired certain
products from DuPont Merck in a management buyout for
$277 million with financing from Kelso & Company, a
private equity investment firm purchased all of Endo
Laboratories L.L.C.'s generic products along with 12
important brand products, including PERCOCET®
and PERCODAN®.
Net sales:
39.4 millions
Employees:
62
Endo licensed LIDODERM® from Hind Healthcare.
Net sales:
108.4 millions
Employees:
70
Endo launched three new strengths of its leading brand-name
drug PERCOCET®. After receiving FDA approval,
Endo launched LIDODERM® as its first new
proprietary, patented product.
Net sales:
135.5 millions
Employees:
92
Endo Pharmaceuticals acquired Algos Pharmaceutical
Corporation through a merger. As a result of this merger,
Endo Pharmaceuticals became a publicly traded company, under
the NASDAQ symbol ENDP.
Net sales:
197.4 millions
Employees:
135
Endo receives FDA approval for new PERCOCET®
strengths (7.5/325 and 10/325 oxycodone/acetaminophen).
Net sales:
252 millions
Employees:
167
Endo established its first internal sales force when it
converted the contract specialty sales force and district
managers into full-time employees to concentrate sales efforts.
Endo reached $1 billion dollars in cumulative sales.
Net sales:
399 millions
Employees:
277
Endo further expands its internal sales force by converting
the contract pharma sales force, district managers and
regional directors to full-time Endo employees.
Net sales:
595.6 millions
Employees:
492
Endo entered into an agreement with Vernalis for the exclusive
rights to market FROVA® in North America. Launched in
the U.S. in June 2002, FROVA is indicated for the acute
treatment of migraine headaches in adults.
Net sales:
615.1 millions
Employees:
594
Endo Pharmaceuticals acquired exclusive licenses from DURECT
Corporation to develop and commercialize a seven-day
transdermal sufentanil patch (EN3270) intended for
moderate-to-severe chronic pain.
Net sales:
820.2 millions
Employees:
710
Endo received FDA approval for OPANA® and OPANA®
ER, which represented the first internally developed NDAs to
be granted FDA approval.
Endo Pharmaceuticals acquires RxKinetix, Inc. through an
acquisition. The acquisition broadens Endo pipeline with
supportive care oncology products, including EN3285, a
topical oral-rinse for the prevention of oral mucositis.
Net sales:
909.7 millions
Employees:
1,024
Endo celebrated its 10-year anniversary.
Roger Kimmel appointed chairman of the Board; Carol Ammon
retired.
Endo entered into a license and development agreement with
Alexza Pharmaceuticals, Inc. for the exclusive clinical
development and commercialization rights in North America
for Alexza's AZ-003/ EN3294. Currently in Phase I, clinical
development, AZ-003 is a hand-held drug device system that
uses Alexza's proprietary Staccato® system
inhalation technology to deliver fentanyl for the treatment
of breakthrough pain in cancer and non-cancer patients.
Net sales:
1,085.6 millions
Employees:
1,208
Endo entered into a licensing agreement with Novartis to
obtain the exclusive U.S. marketing rights for the
prescription medicine Voltaren® Gel (diclofenac
sodium topical gel) 1%. Voltaren Gel received regulatory
approval in October 2007 from the U.S. Food and Drug
Administration, becoming the first topical prescription
treatment for use in treating pain associated with
osteoarthritis and the first new product approved in the
U.S. for osteoarthritis since 2001.
David Holveck is named President, Chief Executive Officer
and a Director of Endo. A new executive team is created to
take Endo to the next level.
On March 23, 2009, Endo Pharmaceuticals successfully
completed its acquisition of Indevus Pharmaceuticals, Inc.
Indevus brought us multiple marketed products that enhance
revenue growth, a specialized infrastructure focused in urology,
endocrinology and oncology, and a strong drug-development pipeline.
No content!
